Les Laboratoires Servier’s two-pronged approach to cancer R&D, focused on immunotherapy and programmed cell death, spans both solid and liquid tumors but homes in on those diseases with a high unmet need.
Talking to Scrip about its pipeline, global head of oncology medical and patient affairs Des Murphy said it addresses rare...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?